Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606782 | 0.98 | GABRA5 (0.48) | GABRA5ALDH1A1KMT2AMAPK14NPC1 | |
| SCHEMBL4605464 | 0.97 | GABRA5 (0.50) | GABRA5ALDH1A1KMT2AMAPK14KDM4E | |
| SCHEMBL14188853 | 0.94 | GABRA5 (0.52) | GABRA5 | |
| SCHEMBL4604140 | 0.92 | GABRA5 (0.49) | GABRA5ALDH1A1KMT2AMAPK14TDP1 | |
| SCHEMBL4986426 | 0.91 | GABRA5 (0.51) | GABRA5ALDH1A1KMT2A | |
| SCHEMBL4979623 | 0.90 | GABRA5 (0.49) | GABRA5ALDH1A1KMT2AMAPK14TDP1 | |
| SCHEMBL4985687 | 0.90 | GABRA5 (0.51) | GABRA5ALDH1A1KMT2A | |
| SCHEMBL4604079 | 0.89 | GABRA5 (0.49) | GABRA5ALDH1A1KMT2AMAPK14TDP1 | |
| SCHEMBL4980741 | 0.88 | GABRA5 (0.53) | GABRA5MAPK14 | |
| SCHEMBL28775772 | 0.87 | KDM4E (0.40) | GABRA5ALDH1A1KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937674-A1 | ISOXAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | claimed |
| US-7378435-B2 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | claimed |
| WO-2007042420-A1 | ISOXAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | claimed |
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-04-12 | — | — | US | claimed |
| EP-1937674-A1 | ISOXAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-7378435-B2 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378435-B2 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378435-B2 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2007042420-A1 | ISOXAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | GABRA5, GABRA4, CHRNA5 | GABRA5 1/4885ALDH1A1 297/4885KMT2A 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.